Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$6.25 USD
-0.36 (-5.45%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $6.33 +0.08 (1.28%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Foghorn Therapeutics Inc. [FHTX]
Reports for Purchase
Showing records 61 - 79 ( 79 total )
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Validating Collaboration Deal with Ideal Partner LLY
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Lily Collaboration Further Strengthens Foghorn?s Gene Control Platform
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Beating the BAF Out of Cancer; Initiating With a Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q3 Financials; Early Data Ahead for FHD-286; Deep in Degradation
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q2 Financials; Clinical Programs Enrolling; R&D Day Highlights
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q1 Financials; IND clearance for FHD-609; R&D Day Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q4 Financials; FHD-286 and FHD-609 Clinical Studies Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q3 Financials; 2021 Is the Year of the Clinic - Reiterate OUTPERFORM and $24 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Seeing Through the Fog; Initiating at OUTPERFORM and $24 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R